MedTrace Logo

A Study Investigating Lu AG22515 in Healthy Adults

NCT05136053 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-08-28

No results posted yet for this study

Summary

The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution).

Conditions

  • Healthy Participants

Interventions

DRUG

Lu AG22515

sterile solution for infusion

DRUG

Placebo

sterile solution for infusion

DRUG

Immune System Activator

sterile powder for injection

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Email contact via H. Lundbeck A/S · H. Lundbeck A/S

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-18
Primary Completion
2023-08-05
Completion
2023-08-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05136053 on ClinicalTrials.gov